HLL
signs MoU with IL&FS for MediPark
AAT
News Service
Hindustan
Latex (HLL), a mini ratna company under the Ministry of
Health and Family Welfare of the Government of India has
signed a Memorandum of Understanding (MoU) with Infrastructure
Leasing and Financial Services (IL&FS) for the development
of its Integrated Medical Devices and Diagnostic Manufacturing
Park, MediPark, and with NNE Pharmaplan for its Integrated
Vaccine Complex, to be set up at Chengalpet near Chennai,
Tamil Nadu.
The
MoU was signed by the Chairman and Managing Director of
HLL, M Ayyappan, with the representatives of the respective
Project Management Consultants, IL&FS and NNE Pharmaplan
at a special function in the Chamber of the Union Secretary,
Health and Family Welfare, Naresh Dayal in New Delhi. MediPark
With the growing demand from pharmaceutical and healthcare
sectors in India, the medical devices and equipment industry
is witnessing a vibrant growth with an estimated market
turnover of Rs 2,500 crore and is projected to grow at 15
per cent annually.
The
MediPark being set up by HLL will be a world-class production
facility for manufacture of medical devices, medical equipment
and medical diagnostics, in over 330 acres of land near
the CLTRI at Chengalpet, and shall comprise state-of-the-art
infrastructure for the production of these devices, with
a view to achieving self reliance in the area of healthcare
commodities. The facility is conceived on a public-private
partnership (PPP) and would have common facilities such
as sterilisation centre, testing and quality control facilities,
waste disposal facility, logistics hub etc.
The
project outlay for infrastructure development alone is expected
to be around Rs 100 crore.
IL&FS is a pioneer in developing industrial clusters/parks
on PPP. IL&FS would identify the prospective investors,
structure the project and provide engineering and financial
services to the project. The project would be developed
as a self-contained facility comprising physical, social
and environmental infrastructure facilities, meeting the
requirements of international markets. The common infrastructure
facilities to be provided at the MediPark will be finalised
through the government by suitable policy interventions.
The
Medipark will bring in latest technologies and systems in
healthcare devices, equipment and diagnostics manufacturing
and would have manufacturers of some of the key sub-segments
in the medical devices & equipment sector like medical
disposables/supplies, medical implants, diagnostics (including
equipment for patient monitoring and rapid diagnostic kits
for infectious diseases, and medical instruments & equipment
(dental, ophthalmic, medical x-ray, alpha, beta, gamma ray
equipment etc). MediPark is expected to provide a fillip
to the medical industry in the country, which currently
depends on imports for almost 60 per cent of its requirement
of medical devices as well as provide an enabling environment
for industries in the healthcare domain to set shop. Integrated
Vaccine ComplexThe ‘Integrated Vaccine Complex’,
will be set up in about 100 acres of land near CLTRI. The
complex will house a production facility for vaccines for
the Universal Immunisation Programme (UIP) and other New
Generation Vaccines, and Vaccine R&D, in accordance
with WHO-cGMP guidelines, to make safe and effective vaccines
available at affordable prices. The Integrated Vaccine Complex
has been accorded the status as ‘a project of national
importance’ by the government.
HLL
has appointed NNE Pharmaplan (India), the world’s leading
engineering and consultancy service organisation for biotechnology
industries, as the project consultant for setting up the
Integrated Vaccine Complex. HLL plans to commission the
first stage of the project within two years in order to
meet the national demand for UIP vaccines. The unit will
be equipped to export the vaccines manufactured in the complex
to international agencies, to fulfil the vast need for children’s
vaccines in several poor countries. The Integrated Vaccine
Complex, will manufacture the conventional bacterial vaccines
for UIP; DPT group of vaccines and BCG vaccine to meet the
national demand, and other new generation vaccines like
Measles vaccines, Hepatitis B, Anti-Rabies, Japanese encephalitis
vaccine and Pentavalant Combination vaccines (DPT-HepB-Hib).
Initially, HLL will do the packaging and marketing of bulk
vaccines procured from other manufacturers and later go
in for primary manufacturing of vaccines from seed strains.
In this connection, HLL has already initiated discussions
with major vaccine manufacturers for possible collaborations.
The
complex will also have a state-of-the-art vaccine R&D
facility to develop new vaccines such as, H5N1 to combat
Bird Flu and other infectious diseases.
HLL
already has a project team in place with the requisite expertise
to successfully implement the project. The initial investment
proposed has an outlay of Rs 150 crore over a period of
20 months and the final investment will be near to Rs 500
crore.
HLL
set up in 1966, is India’s leading providers of a wide
range of contraceptives, hospital products, pharma products,
and healthcare solutions. HLL is today a multi-product organisation,
with five manufacturing units, with its vast array of innovative
products and services, enjoying a strong presence in the
commercial and social sector segments across the country,
addressing various public health challenges. HLL is today
on the path of rapid growth, having drawn up a comprehensive
plan to expand its portfolio in the area of healthcare and
contraceptives, through technical collaborations, marketing
alliances and joint ventures. With its vision of ‘Innovating
for Healthy Generations’, HLL wishes to keep alive
the dream of all humanity – of a healthier, happier
world.
